Search Within

Myeloma

Formats
  1. Meeting Abstract (556)
  2. Journal Article (360)
  3. Review (36)
  4. Research Letter (21)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (1005)
  2. Department of Medicine (1005)
  3. Hematologic Malignancies, Division of (1005)
  4. Hematologic Malignancies Research (663)
  5. Survivorship Research (369)
  6. Bone Marrow Transplant (300)

More Groups

People
  1. Alexander Lesokhin (375)
  2. Carl Landgren (336)
  3. Hani Hassoun (335)
  4. Sham Mailankody (293)
  5. Malin Hultcrantz (268)
  6. Heather Landau (246)

More People

Years
  1. 2025 (17)
  2. 2024 (82)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (316)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (23)

More Publications

Publishers
  1. American Society of Hematology (338)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (84)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (1005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Journal Article

    Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Multiple myeloma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology
    Guidelines

    Kumar, S. K.; Callander, N. S.; Adekola, K.; Anderson, L. D.; Baljevic, M.; Baz, R.; Campagnaro, E.; Castillo, J. J.; Costello, C.; D'Angelo, C.; more...
    Journal of the National Comprehensive Cancer Network (2023)

    Fulltext@MSK | Save
  • Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: Results from the population-based iStopMM study
    Journal Article

    Sigurbergsdóttir, A. Ý; Rögnvaldsson, S.; Thorsteinsdóttir, S.; Sverrisdóttir, I.; Sigurðardóttir, G. Á; Viðarsson, B.; Önundarson, P. T.; Agnarsson, B. A.; Sigurðardóttir, M.; Þorsteinsdóttir, I.; more...
    Haematologica (2023)

    Fulltext@MSK | Save
  • Current use of CAR T cells to treat multiple myeloma
    Review

    Firestone, R. S.; Mailankody, S.
    Hematology-American Society of Hematology Education Program (2023)

    Fulltext@MSK | Save
  • Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse national health and nutrition examination survey (NHANES) case-control study
    Meeting Abstract

    Joseph, J.; Tang, L.; Hillengass, J.; Landgren, O.; Usmani, S.; Lesokhin, A.; Moysich, K.; Shah, U.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: Post-hoc analysis from MagnetisMM-3
    Meeting Abstract

    Leleu, X.; Bahlis, N.; Rodríguez-Otero, P.; Quach, H.; Touzeau, C.; Depaus, J.; Iida, S.; Hänel, M.; Wrobel, T.; Leip, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Jagannath, S.; Martin, T.; Usmani, S.; Berdeja, J.; Jakubowiak, A.; Agha, M.; Cohen, A.; Deol, A.; Htut, M.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save